EUVIMEDEUVIMED entdecken
Open Access

Performance of thermoablation among women treated for high‐risk human papillomavirus in a screen‐and‐treat program in South Africa

Melanie Jenkins, Rakiya Saidu, Rosalind Boa, Nomonde Mbatani, Jennifer Moodley, Louise Kuhn iD

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35519 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Melanie Jenkins und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Heilbrunn Department of Population and Family Health, Mailman School of Public Health, Columbia University Irving Medical Center, New York, New Y…. Hauptthemen laut MEDLINE: Papillomavirus Infections, Uterine Cervical Neoplasms, Uterine Cervical Dysplasia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thermal ablation is a simple treatment option for HPV‐associated, pre‐cancerous disease, has a low risk of complications and can be undertaken by non‐specialists. For these reasons, it is one of the recommended treatment modalities for cervical cancer screening programs. As part of a screen‐and‐treat demonstration study, 3060 women living with and without HIV, aged 30–65 years, were recruited at an urban site in South Africa. HPV testing stratified the population into those at highest risk for precancerous disease, identifying 529 (17.3%) women with high HPV viral loads on select HPV genotypes and multi‐channel infections indicating their need for treatment. Among this group, visual assessment criteria further stratified this at‐risk population into those suitable versus unsuitable for ablative therapy. 483 (91.3%) of 529 women met visual criteria defining their suitability for ablative treatment and all were treated with thermoablation. Women were followed at 6‐ and 12‐months where HPV testing and colposcopy with histological sampling were performed. HPV persistence at 12 months despite treatment was 51.8%, and detection of histologically confirmed cervical intraepithelial neoplasia grade 2 or higher occurred in 24.0%. Being HIV‐positive, older age, multi‐channel infection, high HPV viral load, and low CD4 count were associated with these indicators of treatment failure. Cervical cancer screening programs that target treatment to the highest risk women are likely to observe higher indicators of treatment failure than less focused programs. Although thermoablation is an approved treatment modality, our results highlight the urgency of finding more effective but safe and practical treatment options for precancerous disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus InfectionsUterine Cervical NeoplasmsUterine Cervical DysplasiaHumansFemaleMiddle AgedSouth AfricaAdultAgedPapillomaviridaeEarly Detection of CancerHIV InfectionsColposcopyViral LoadPrecancerous ConditionsHuman Papillomavirus Viruses

Stichwörter der Autor:innen

cervical intraepithelial neoplasiahuman papillomavirusscreeningthermoablation

Autor:innen und Institutionen

  • The Heilbrunn Department of Population and Family Health, Mailman School of Public Health, Columbia University Irving Medical Center, New York, New York, USA.
  • Gertrude H. Sergievsky Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York, USA.
  • Department Obstetrics and Gynaecology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
  • South African Medical Research Council, Gynaecology Cancer Research Centre, Department Obstetrics and Gynaecology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
  • Cancer Research Initiative and School of Public Health, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
  • Department of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, New York, New York, USA.

ORCID-Profile: Louise Kuhn

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Jenkins, M., Saidu, R., Boa, R., Mbatani, N., Moodley, J., & Kuhn, L. (2025). Performance of thermoablation among women treated for high‐risk human papillomavirus in a screen‐and‐treat program in South Africa. International Journal of Cancer. https://doi.org/10.1002/ijc.35519

Vancouver

Jenkins M, Saidu R, Boa R, Mbatani N, Moodley J, Kuhn L. Performance of thermoablation among women treated for high‐risk human papillomavirus in a screen‐and‐treat program in South Africa. International Journal of Cancer. 2025. doi:10.1002/ijc.35519

BibTeX
@article{Jenkins2025,
  author = {Jenkins, Melanie and Saidu, Rakiya and Boa, Rosalind and Mbatani, Nomonde and Moodley, Jennifer and Kuhn, Louise},
  title = {Performance of thermoablation among women treated for high‐risk human papillomavirus in a screen‐and‐treat program in South Africa},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35519}
}
Kostenlos starten →